Motzer, Robert John

selected publications

Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 15
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. The Lancet. Oncology. 2019 Academic Article GET IT
Times cited: 123
Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply. The New England journal of medicine. 2019 Article GET IT
Times cited: 1
Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 22
Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 186
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet (London, England). 2019 Academic Article GET IT
Times cited: 343
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. European journal of cancer. 2019 Academic Article GET IT
Times cited: 94
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future oncology (London, England). 2019 Academic Article GET IT
Times cited: 21
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 82
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. The Lancet. Oncology. 2019 Academic Article GET IT
Times cited: 208
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer discovery. 2019 Academic Article GET IT
Times cited: 162
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. The Lancet. Oncology. 2018 Academic Article GET IT
Times cited: 111
Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 18
Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. British journal of cancer. 2018 Editorial Article GET IT
Times cited: 8
PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 15
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. European urology. 2018 Information Resource GET IT
Times cited: 82
Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience. Urology. 2018 Academic Article GET IT
Times cited: 8
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 37
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British journal of cancer. 2018 Academic Article GET IT
Times cited: 68
Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA oncology. 2018 Academic Article GET IT
Times cited: 129
The role of tivozanib in advanced renal cell carcinoma therapy. Expert review of anticancer therapy. 2018 Information Resource GET IT
Times cited: 7
Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018 Article GET IT
Times cited: 9
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature medicine. 2018 Academic Article GET IT
Times cited: 927
Cytoreductive Nephrectomy - Patient Selection Is Key. The New England journal of medicine. 2018 Editorial Article GET IT
Times cited: 50
Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 44
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. Journal of hematology & oncology. 2018 Academic Article GET IT
Times cited: 29
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 27
Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018 Academic Article GET IT
Times cited: 7
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancer immunology research. 2018 Academic Article GET IT
Times cited: 98
Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clinical genitourinary cancer. 2018 Academic Article GET IT
Times cited: 49
Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. Urology. 2018 Academic Article GET IT
Times cited: 7
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. British journal of cancer. 2018 Academic Article GET IT
Times cited: 63
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 3421
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. European journal of cancer. 2018 Academic Article GET IT
Times cited: 31
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis. BMC cancer. 2018 Academic Article GET IT
Times cited: 4
Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. Urology. 2018 Academic Article GET IT
Times cited: 13
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 47
Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 21
Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 52
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science (New York, N.Y.). 2018 Academic Article GET IT
Times cited: 863
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. Urologic oncology. 2017 Academic Article GET IT
Times cited: 21
Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8. European urology. 2017 Article GET IT
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 29
Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European urology focus. 2017 Academic Article GET IT
Times cited: 28
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. European urology. 2017 Academic Article GET IT
Times cited: 174
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. European urology focus. 2017 Academic Article GET IT
Times cited: 38
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 330
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017 Academic Article GET IT
Times cited: 369
Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. Kidney cancer (Clifton, Va.). 2017 Academic Article GET IT
Times cited: 39
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. Japanese journal of clinical oncology. 2017 Academic Article GET IT
Times cited: 50
Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. Clinical genitourinary cancer. 2017 Academic Article GET IT
Times cited: 10
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings. Journal of the European Academy of Dermatology and Venereology : JEADV. 2017 Article GET IT
Times cited: 60
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. Clinical genitourinary cancer. 2017 Academic Article GET IT
Times cited: 36
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. European urology. 2017 Academic Article GET IT
Times cited: 146
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urologic oncology. 2017 Academic Article GET IT
Times cited: 22
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. European urology. 2017 Academic Article GET IT
Times cited: 131
Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. Clinical genitourinary cancer. 2017 Academic Article GET IT
Times cited: 7
Systemic Therapy for Metastatic Renal-Cell Carcinoma. The New England journal of medicine. 2017 Information Resource GET IT
Times cited: 504
Kidney cancer in 2016: The evolution of anti-angiogenic therapy for kidney cancer. Nature reviews. Nephrology. 2017 Information Resource GET IT
Times cited: 19
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 68
Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. Urology. 2016 Academic Article GET IT
Times cited: 12
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. The oncologist. 2016 Academic Article GET IT
Times cited: 73
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. European urology. 2016 Academic Article GET IT
Times cited: 166
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. The New England journal of medicine. 2016 Academic Article GET IT
Times cited: 413
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature communications. 2016 Academic Article GET IT
Times cited: 145
Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. The Journal of urology. 2016 Academic Article GET IT
Times cited: 10
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA oncology. 2016 Academic Article GET IT
Times cited: 158
Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. European urology focus. 2016 Academic Article GET IT
Times cited: 28
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. European urology focus. 2016 Academic Article GET IT
Times cited: 39
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nature reviews. Urology. 2016 Review GET IT
Times cited: 83
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. The oncologist. 2016 Academic Article GET IT
Times cited: 83
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 194
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 529
Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. Urology. 2016 Academic Article GET IT
Times cited: 3
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 35
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clinical genitourinary cancer. 2016 Academic Article GET IT
Times cited: 8
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 64
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Targeted oncology. 2016 Academic Article GET IT
Times cited: 17
Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours. European journal of cancer. 2016 Academic Article GET IT
Times cited: 17
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 106
Treatment of Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2016 Article GET IT
Times cited: 12
Immune Checkpoint Therapy in Renal Cell Carcinoma. Cancer journal (Sudbury, Mass.). 2016 Information Resource GET IT
Times cited: 20
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. British journal of cancer. 2016 Academic Article GET IT
Times cited: 40
Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer. 2016 Academic Article GET IT
Times cited: 31
Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. The Lancet. Oncology. 2015 Article GET IT
Times cited: 88
A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma. Future oncology (London, England). 2015 Academic Article GET IT
Times cited: 18
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 37
Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma. The Urologic clinics of North America. 2015 Information Resource GET IT
Times cited: 10
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer. 2015 Academic Article GET IT
Times cited: 17
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 511
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. British journal of cancer. 2015 Academic Article GET IT
Times cited: 88
The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Article GET IT
Times cited: 2
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 1030
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 4820
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 7
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. European urology. 2015 Academic Article GET IT
Times cited: 57
Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 17
Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Review GET IT
Times cited: 10
Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 8
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British journal of cancer. 2015 Academic Article GET IT
Times cited: 33
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 28
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 165
Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience. The Journal of urology. 2014 Academic Article GET IT
Times cited: 38
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 923
Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. Urologic oncology. 2014 Information Resource GET IT
Times cited: 8
Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. The Journal of urology. 2014 Academic Article GET IT
Times cited: 19
The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer medicine. 2014 Academic Article GET IT
Times cited: 100
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer chemotherapy and pharmacology. 2014 Academic Article GET IT
Times cited: 66
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 313
Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial. Cancer medicine. 2014 Academic Article GET IT
Times cited: 8
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. European journal of cancer. 2014 Academic Article GET IT
Times cited: 61
Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis. Clinical genitourinary cancer. 2014 Academic Article GET IT
Times cited: 30
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. British journal of cancer. 2014 Academic Article GET IT
Times cited: 86
Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example. PloS one. 2014 Academic Article GET IT
Times cited: 26
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. European urology. 2014 Information Resource GET IT
Times cited: 108
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. The New England journal of medicine. 2014 Article GET IT
Times cited: 199
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. European journal of cancer. 2014 Academic Article GET IT
Times cited: 16
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. Cancer. 2014 Academic Article GET IT
Times cited: 16
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 178
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Targeted oncology. 2014 Academic Article GET IT
Times cited: 45
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 237
Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. The Journal of urology. 2014 Academic Article GET IT
Times cited: 43
Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma. The Journal of urology. 2014 Academic Article GET IT
Times cited: 15
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
Times cited: 73
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. British journal of cancer. 2014 Academic Article GET IT
Times cited: 63
Kidney cancer in 2013: From molecular understanding to clinical advances. Nature Reviews Urology. 2014 Article GET IT
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 319
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. Journal of the National Cancer Institute. 2013 Academic Article GET IT
Times cited: 234
Pazopanib versus sunitinib in renal cancer. The New England journal of medicine. 2013 Article GET IT
Times cited: 31
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 51
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 85
Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology. 2013 Academic Article GET IT
Times cited: 239
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Article GET IT
Times cited: 28
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. European journal of cancer. 2013 Academic Article GET IT
Times cited: 60
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 350
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 1212
Intra- and interobserver variability in CT measurements in oncology. Radiology. 2013 Academic Article GET IT
Times cited: 59
Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clinical genitourinary cancer. 2013 Academic Article GET IT
Times cited: 53
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. British journal of cancer. 2013 Academic Article GET IT
Times cited: 120
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 295
Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer. 2013 Academic Article GET IT
Times cited: 22
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. The Lancet. Oncology. 2013 Academic Article GET IT
Times cited: 512
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. British journal of cancer. 2013 Academic Article GET IT
Times cited: 55
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. Journal of clinical pharmacology. 2013 Academic Article GET IT
Times cited: 132
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Investigational new drugs. 2013 Academic Article GET IT
Times cited: 38
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell reports. 2013 Academic Article GET IT
Times cited: 29
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clinical genitourinary cancer. 2013 Academic Article GET IT
Times cited: 39
Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma. Cancer journal (Sudbury, Mass.). 2013 Review GET IT
Times cited: 8
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. European urology. 2012 Academic Article GET IT
Times cited: 29
Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. The Journal of urology. 2012 Academic Article GET IT
Times cited: 32
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. European urology. 2012 Academic Article GET IT
Times cited: 181
Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial. BMC cancer. 2012 Academic Article GET IT
Times cited: 34
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Information Resource GET IT
Times cited: 88
Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene. 2012 Academic Article GET IT
Times cited: 117
Ten years of progress in renal cell carcinoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2012 Academic Article GET IT
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α. British journal of cancer. 2012 Academic Article GET IT
Times cited: 29
Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC). BJU international. 2012 Academic Article GET IT
Times cited: 30
Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site. Urology. 2012 Academic Article GET IT
Times cited: 6
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. British journal of cancer. 2012 Academic Article GET IT
Times cited: 20
Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012 Academic Article GET IT
Times cited: 23
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 207
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 55
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma. British journal of cancer. 2012 Academic Article GET IT
Times cited: 28
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. European urology. 2012 Academic Article GET IT
Times cited: 54
Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology. 2012 Academic Article GET IT
Times cited: 20
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. European journal of cancer. 2011 Academic Article GET IT
Times cited: 105
Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. Urology. 2011 Academic Article GET IT
Times cited: 17
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (London, England). 2011 Academic Article GET IT
Times cited: 1403
Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. American journal of clinical oncology. 2011 Academic Article GET IT
Times cited: 73
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011 Academic Article GET IT
Times cited: 104
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 158
mTOR inhibitors in advanced renal cell carcinoma. Hematology/oncology clinics of North America. 2011 Review GET IT
Times cited: 103
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer. 2011 Academic Article GET IT
Times cited: 42
High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. Expert review of anticancer therapy. 2011 Review GET IT
Times cited: 16
Resection of primary mediastinal non-seminomatous germ cell tumors: a 28-year experience at memorial sloan-kettering cancer center. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 30
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. European urology. 2011 Information Resource GET IT
Times cited: 97
Sequelae of treatment in long-term survivors of testis cancer. European urology. 2011 Information Resource GET IT
Times cited: 59
Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. International journal of radiation oncology, biology, physics. 2011 Academic Article GET IT
Times cited: 183
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute. 2011 Academic Article GET IT
Times cited: 510
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. Hematology/oncology clinics of North America. 2011 Review GET IT
Times cited: 14
Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. The oncologist. 2011 Academic Article GET IT
Times cited: 25
Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update. Urology. 2011 Academic Article GET IT
Times cited: 11
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. Journal of the National Comprehensive Cancer Network : JNCCN. 2011 Academic Article GET IT
Times cited: 50
Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. The oncologist. 2011 Information Resource GET IT
Times cited: 69
Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. The Journal of urology. 2010 Academic Article GET IT
Times cited: 65
Contemporary lymph node counts during primary retroperitoneal lymph node dissection. Urology. 2010 Academic Article GET IT
Times cited: 14
Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. American journal of clinical oncology. 2010 Academic Article GET IT
Times cited: 27
Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. Cancer. 2010 Academic Article GET IT
Times cited: 27
Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression. Cancer research. 2010 Academic Article GET IT
Times cited: 30
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010 Academic Article GET IT
Times cited: 970
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Investigational new drugs. 2010 Academic Article GET IT
Times cited: 80
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 125
The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Academic Article GET IT
Times cited: 44
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. American journal of respiratory and critical care medicine. 2010 Academic Article GET IT
Times cited: 171
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 201
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. British journal of cancer. 2010 Academic Article GET IT
Times cited: 50
Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer. 2010 Academic Article GET IT
Times cited: 42
Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Editorial Article GET IT
Times cited: 15
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Investigational new drugs. 2009 Academic Article GET IT
Times cited: 60
Good-risk-advanced germ cell tumors: historical perspective and current standards of care. World journal of urology. 2009 Information Resource GET IT
Times cited: 10
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 2026
Targeting renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Editorial Article GET IT
Times cited: 53
Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa. Journal of oncology practice. 2009 Academic Article GET IT
Times cited: 34
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. 2009 GET IT
Times cited: 270
Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clinical genitourinary cancer. 2009 Academic Article GET IT
Times cited: 58
Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008 Academic Article GET IT
Times cited: 7
Systemic therapy for metastatic renal cell carcinoma. The Urologic clinics of North America. 2008 Information Resource GET IT
Times cited: 34
Clinical outcome and predictors of survival in late relapse of germ cell tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 85
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. The oncologist. 2008 Information Resource GET IT
Times cited: 171
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008 Academic Article GET IT
Times cited: 162
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 70
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 99
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (London, England). 2008 Academic Article GET IT
Times cited: 2495
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. The Journal of urology. 2008 Academic Article GET IT
Times cited: 126
American society of clinical oncology. P & T : a peer-reviewed journal for formulary management. 2008 Academic Article GET IT
Stage I testicular cancer management and necessity for surgical expertise. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Editorial Article GET IT
Times cited: 11
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008 Academic Article GET IT
Times cited: 4
Expression of prostate-specific membrane antigen in renal cortical tumors. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2008 Academic Article GET IT
Times cited: 18
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. The American journal of surgical pathology. 2008 Academic Article GET IT
Times cited: 77
Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. Clinical genitourinary cancer. 2008 Academic Article GET IT
Times cited: 15
The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. Cancer. 2008 Academic Article GET IT
Times cited: 17
Medical treatment of advanced testicular cancer. JAMA. 2008 Review GET IT
Times cited: 270
Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors? Commentary. Nature Clinical Practice Urology. 2008 Article GET IT
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Investigational new drugs. 2007 Academic Article GET IT
Times cited: 16
Targeted drugs for metastatic renal cell carcinoma. Lancet (London, England). 2007 Article GET IT
Times cited: 54
Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?. Nature clinical practice. Urology. 2007 Comment GET IT
Times cited: 1
Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 85
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 58
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The Lancet. Oncology. 2007 Academic Article GET IT
Times cited: 407
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 109
Sunitinib efficacy against advanced renal cell carcinoma. The Journal of urology. 2007 Academic Article GET IT
Times cited: 177
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 112
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. Journal of translational medicine. 2007 Academic Article GET IT
Times cited: 294
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute. 2007 Letter GET IT
Times cited: 16
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England journal of medicine. 2007 Academic Article GET IT
Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Investigational new drugs. 2007 Academic Article GET IT
Times cited: 21
Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors. The Urologic clinics of North America. 2007 Information Resource GET IT
Times cited: 4
Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. BJU international. 2007 Academic Article GET IT
Times cited: 21
Phase III randomized trial in patients with poor-prognosis metastatic germ cell tumors. American Journal of Hematology/ Oncology. 2007 Article
Sunitinib and hypothyroidism. The New England journal of medicine. 2007 Article GET IT
Times cited: 34
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. The Journal of urology. 2007 Academic Article GET IT
Times cited: 58
Interferon-alpha resistance associated genes in renal cell carcinoma identified by expression profiling. The Journal of urology. 2007 Academic Article GET IT
Times cited: 3
Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. The Journal of urology. 2007 Academic Article GET IT
Times cited: 74
Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. TheScientificWorldJournal. 2007 Academic Article GET IT
Times cited: 37
Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 70
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 278
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England journal of medicine. 2007 Academic Article GET IT
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 96
Chemotherapy for advanced germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Information Resource GET IT
Times cited: 50
Targeted therapy for metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Information Resource GET IT
Times cited: 249
Novel targets and therapies for metastatic renal cell carcinoma. Oncology (Williston Park, N.Y.). 2006 Review GET IT
Times cited: 15
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Investigational new drugs. 2006 Academic Article GET IT
Times cited: 122
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006 Academic Article GET IT
Times cited: 84
A brief symptom index for advanced renal cell carcinoma. Health and quality of life outcomes. 2006 Academic Article GET IT
Times cited: 9
Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. The Journal of urology. 2006 Academic Article GET IT
Times cited: 56
Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 185
Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006 Academic Article GET IT
Times cited: 1080
Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU international. 2006 Academic Article GET IT
Times cited: 57
Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert opinion on investigational drugs. 2006 Information Resource GET IT
Times cited: 107
Medullary renal cell carcinoma and response to therapy with bortezomib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Article GET IT
Times cited: 34
Transcriptional program associated with IFN-alpha response of renal cell carcinoma. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2006 Academic Article GET IT
Times cited: 2
Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 88
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 1464
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 66
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 283
Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. The Journal of urology. 2005 Academic Article GET IT
Times cited: 83
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU international. 2005 Information Resource GET IT
Times cited: 47
Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 155
A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. The Journal of urology. 2005 Academic Article GET IT
Times cited: 384
Innovations and challenges in renal cancer: consensus statement from the first international conference. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Conference Paper GET IT
Times cited: 36
Phase II trial of bortezomib for patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 152
Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2004 Academic Article GET IT
Times cited: 88
Editorial: predicting necrosis after chemotherapy for advanced nonseminomatous germ cell tumor-surrogate end points, decreasing morbidity and patient outcome. The Journal of urology. 2004 Editorial Article GET IT
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. Investigational new drugs. 2004 Academic Article GET IT
Times cited: 12
Ototoxicity in patients with dose-intensive therapy for cisplatin-resistant germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Article GET IT
Times cited: 9
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 648
Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 72
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Annals of surgical oncology. 2004 Academic Article GET IT
Times cited: 224
Chemotherapy for teratoma with malignant transformation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 156
Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groups. The Urologic clinics of North America. 2003 Information Resource GET IT
Times cited: 10
Poor-risk testicular cancer and high-dose chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Editorial Article GET IT
Times cited: 4
Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. Cancer. 2003 Academic Article GET IT
Times cited: 31
Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. The Journal of urology. 2003 Academic Article GET IT
Times cited: 44
Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology. 2003 Academic Article GET IT
Times cited: 72
Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. The Journal of urology. 2003 Academic Article GET IT
Times cited: 17
Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Investigational new drugs. 2003 Academic Article GET IT
Times cited: 81
Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 18
Recommendations of follow-up after treatment of germ cell tumors. Seminars in oncology. 2003 Information Resource GET IT
Times cited: 14
Long-term follow-up of bilateral sporadic renal tumors. Urology. 2003 Academic Article GET IT
Times cited: 42
Renal cell carcinoma: a priority malignancy for development and study of novel therapies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Editorial Article GET IT
Times cited: 28
The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU international. 2003 Academic Article GET IT
Times cited: 40
Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Investigational new drugs. 2003 Academic Article GET IT
Times cited: 141
Prognostic factors for metastatic kidney cancer. Cancer treatment and research. 2003 Information Resource GET IT
Times cited: 3
Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology. 2002 Academic Article GET IT
Times cited: 116
Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors. Seminars in urologic oncology. 2002 Information Resource GET IT
Times cited: 3
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2002 Academic Article GET IT
Times cited: 48
Partial nephrectomy: the rationale for expanding the indications. Annals of surgical oncology. 2002 Academic Article GET IT
Times cited: 51
Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Investigational new drugs. 2002 Academic Article GET IT
Times cited: 71
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 384
Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. The Journal of urology. 2002 Academic Article GET IT
Times cited: 41
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 1289
Phase II trial of thalidomide for patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 124
Salvage chemotherapy for patients with advanced pure seminoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 50
Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical features. International journal of surgical pathology. 2002 Academic Article GET IT
Times cited: 67
A postoperative prognostic nomogram for renal cell carcinoma. The Journal of urology. 2001 Academic Article GET IT
Times cited: 576
Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. The British journal of dermatology. 2001 Academic Article GET IT
Times cited: 378
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 113
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 86
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2001 Academic Article GET IT
Times cited: 91
Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 87
Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 72
Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Investigational new drugs. 2001 Academic Article GET IT
Times cited: 25
The Srinivas article reviewed. ONCOLOGY. 2000 Article
Cytokine therapy in renal cell cancer. Urologic oncology. 2000 Academic Article GET IT
Calvert's formula for dosing carboplatin: overview and concerns of applicability in high-dose setting. Journal of the National Cancer Institute. 2000 Academic Article GET IT
Times cited: 14
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Investigational new drugs. 2000 Academic Article GET IT
Times cited: 12
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Carcinoid tumor of the kidney. The use of somatostatin receptor scintigraphy in diagnosis and management. Urologic oncology. 2000 Academic Article GET IT
Novel investigative approaches for advanced renal cell carcinoma. Seminars in oncology. 2000 Information Resource GET IT
Times cited: 24
Renal cell carcinoma: progress against an elusive tumor. Seminars in oncology. 2000 Article GET IT
Times cited: 5
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Systemic therapy for renal cell carcinoma. The Journal of urology. 2000 Information Resource GET IT
Times cited: 535
Management of renal cell carcinoma. Oncology (Williston Park, N.Y.). 2000 Academic Article GET IT
Times cited: 17
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 1407
Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 52
Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. Clinical pharmacology and therapeutics. 1999 Academic Article GET IT
Times cited: 36
Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer research. 1998 Academic Article GET IT
Times cited: 86
Aminopeptidase A expression and enzymatic activity in primary human renal cancers. International journal of oncology. 1998 Academic Article GET IT
Times cited: 20
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 186
Poor prognosis germ cell tumors: current status and future directions. Seminars in oncology. 1998 Information Resource GET IT
Times cited: 19
Metastatic germ cell tumors: modeling for response to chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma. Investigational new drugs. 1998 Academic Article GET IT
Times cited: 7
Adjuvant chemotherapy for testicular cancer. Surgical oncology clinics of North America. 1997 Information Resource GET IT
Times cited: 5
Testicular germ-cell cancer. The New England journal of medicine. 1997 Information Resource GET IT
Times cited: 730
High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Investigational new drugs. 1997 Academic Article GET IT
Times cited: 28
Do all germ cell tumor patients with residual masses in multiple sites require postchemotherapy resections?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Article GET IT
Germ cell tumors. Current therapy in endocrinology and metabolism. 1997 Information Resource GET IT
Times cited: 1
Optimal management of residual mass after chemotherapy in advanced seminoma: there is time for everything. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Article GET IT
Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Editorial Article GET IT
Renal-cell carcinoma. The New England journal of medicine. 1996 Information Resource GET IT
Times cited: 1512
Adjuvant chemotherapy in pathologic Stage II nonseminomatous testicular cancer: are two cycles of etoposide-cisplatin a standard option?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Article GET IT
Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clinical cancer research : an official journal of the American Association for Cancer Research. 1996 Academic Article GET IT
Times cited: 65
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Expression of the retinoblastoma gene product in renal tumors. Anticancer research. 1996 Academic Article GET IT
Times cited: 14
Defining new standards for adjuvant therapy of testis cancer: a reply. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Article GET IT
Times cited: 1
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
What is the role of nephrectomy in patients with metastatic renal cell carcinoma?. Seminars in Oncology. 1996 Article
Adjuvant chemotherapy for patients with stage II nonseminomatous testis cancer. Seminars in oncology. 1995 Information Resource GET IT
Times cited: 3
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 55
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995 Academic Article GET IT
Times cited: 235
all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer. 1995 Academic Article GET IT
Times cited: 25
Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 153
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 87
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 100
Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Investigational new drugs. 1995 Academic Article GET IT
Times cited: 28
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 175
The management of patients with advanced germ cell tumors. Seminoma and nonseminoma. The Urologic clinics of North America. 1994 Information Resource GET IT
Times cited: 8
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. Journal of the National Cancer Institute. 1994 Academic Article GET IT
Times cited: 466
Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer. 1994 Academic Article GET IT
Times cited: 31
Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer. 1994 Academic Article GET IT
Times cited: 63
Clinical relevance of the i(12p) marker chromosome in germ cell tumors. Journal of the National Cancer Institute. 1994 Academic Article GET IT
Times cited: 102
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 130
Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. Archives of otolaryngology--head & neck surgery. 1994 Academic Article GET IT
Times cited: 34
Germ cell tumors. Current therapy in endocrinology and metabolism. 1994 Academic Article GET IT
Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Investigational new drugs. 1994 Academic Article GET IT
Times cited: 22
Phase II trial of topotecan in patients with advanced renal cell carcinoma. Investigational new drugs. 1994 Academic Article GET IT
Times cited: 34
Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer. 1993 Academic Article GET IT
Times cited: 17
Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. Journal of the National Cancer Institute. 1993 Academic Article GET IT
Times cited: 141
Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer research. 1993 Academic Article GET IT
Times cited: 48
Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 246
Optimal treatment for advanced seminoma?. Cancer. 1993 Editorial Article GET IT
Times cited: 8
Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial. Cancer. 1993 Academic Article GET IT
Times cited: 52
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 289
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 98
A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer. Investigational new drugs. 1993 Academic Article GET IT
Times cited: 3
Role of adjuvant chemotherapy in patients with stage II nonseminomatous germ-cell tumors. The Urologic clinics of North America. 1993 Information Resource GET IT
Times cited: 16
Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. Journal of the National Cancer Institute. 1993 Academic Article GET IT
Times cited: 107
The current status of salvage chemotherapy for patients with cisplatin-resistant germ cell tumors. Cancer investigation. 1993 Editorial Article GET IT
Times cited: 2
The evolving role of chemotherapy of germ cell tumors. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 1993 Information Resource GET IT
Times cited: 1
A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. Human gene therapy. 1992 Academic Article GET IT
Times cited: 27
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. The Journal of urology. 1992 Academic Article GET IT
Times cited: 79
Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. Seminars in oncology. 1992 Academic Article GET IT
Times cited: 28
High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. Journal of the National Cancer Institute. 1992 Information Resource GET IT
Times cited: 83
Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. Investigational new drugs. 1992 Academic Article GET IT
Times cited: 11
Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer. 1992 Academic Article GET IT
Times cited: 87
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer research. 1992 Academic Article GET IT
Times cited: 49
Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow. Bone marrow transplantation. 1992 Academic Article GET IT
Times cited: 32
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992 Academic Article GET IT
Times cited: 69
Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy. Cancer research. 1992 Academic Article GET IT
Times cited: 51
Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992 Academic Article GET IT
Times cited: 114
High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer. 1992 Academic Article GET IT
Times cited: 110
Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer. 1991 Academic Article GET IT
Times cited: 139
The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer. 1990 Academic Article GET IT
Times cited: 109
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. Investigational new drugs. 1990 Academic Article GET IT
Times cited: 14
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990 Academic Article GET IT
Times cited: 240
The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients. Cancer. 1990 Academic Article GET IT
Times cited: 19
Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. Cancer. 1990 Academic Article GET IT
Times cited: 30
Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. Journal of the National Cancer Institute. 1990 Academic Article GET IT
Times cited: 123
Infrequent ras oncogene point mutations in renal cell carcinoma. The Journal of urology. 1990 Academic Article GET IT
Times cited: 62
Blood group-related antigens in human germ cell tumors. Cancer research. 1988 Academic Article GET IT
Times cited: 24
Advanced seminoma: the role of chemotherapy and adjunctive surgery. Annals of internal medicine. 1988 Academic Article GET IT
Times cited: 76
Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1987 Academic Article GET IT
Times cited: 111
Chemotherapy for germ cell tumors. The Urologic clinics of North America. 1987 Information Resource GET IT
Times cited: 12
Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin. Cancer treatment reports. 1987 Academic Article GET IT
Times cited: 30

VIVO Weill Cornell Medical College

Robert John Motzer Professor of Medicine

Publications

selected publications

Contact

full name

Phone

Publications

selected publications

Contact

full name